RankAlpha logo
Back to Rankings

ZVRA

Zevra TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The checked company sources support a better post-earnings setup: Q1 revenue materially outgrew last year, MIPLYFFA revenue and enrollments continued to build, the SDX sale added liquidity, and debt repayment left Zevra with a stronger balance sheet and more strategic flexibility [#8-K-2026-05-06] [#10-Q-2026-05-06]. AP/Zacks coverage also framed the quarter as a revenue and adjusted EPS beat versus consensus.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Celiprolol's DiSCOVER study remains event-driven and still had only 62 enrolled patients and two confirmed events as of March 31, 2026, leaving regulatory timing and readout cadence uncertain [#10-Q-2026-05-06].
Momentum
71
Value
52
Sentiment
49
Setup hits (3d)
— · Net —
AI TargetsBase $13.00 · Bull $18.00 · Bear $7.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $27.89
Why
Momentum71 · Δ7d +1.0
Value52 · Δ7d +0.0
Sentiment49 · Δ7d +1.5
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Value · See fundamentals
Momentum
71
26% active weight
Current posture
7d trendImproving
Δ7d
+1.0
Δ21d
-3.8
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.1
Sentiment
49
34% active weight
Current posture
7d trendImproving
Δ7d
+1.5
Δ21d
+4.5
Why this grade

Composite grade B. Momentum 71.2 / Value 52.2 / Sentiment 48.7

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$754.9M
Beta
0.99
Shares Out
59.12M
P/E (TTM)
14.1
P/S (TTM)
5.56
P/FCF (TTM) · Derived
64.36
Rev YoY
+77.5%
EPS YoY
-1152.4%
Gross Margin
+83.9%
Op Margin
-103.9%
Net Debt
-$127.81M
Current Ratio
4.89
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology